Binaltorphimine
![]() | |
Systematic (IUPAC) name | |
---|---|
(1S,2S,7S,8S,12R,20R,24R,32R)-11,33-bis(cyclopropylmethyl)-22-methyl-19,25-dioxa-11,22,33-triazaundecacyclo[24.9.1.18,14.01,24.02,32.04,23.05,21.07,12.08,20.018,37.030,36]heptatriaconta-4(23),5(21),14(37),15,17,26(36),27,29-octaene-2,7,17,27-tetrol | |
Clinical data | |
Identifiers | |
105618-27-7 | |
None | |
PubChem | CID 5484197 |
ChemSpider | 4588407 |
Chemical data | |
Formula | C41H45N3O6 |
675.813 g/mol | |
SMILES
| |
|
Binaltorphimine (BNI) is a selective antagonist of the κ-opioid receptor (KOR).[1] BNI and norbinaltorphimine (nor-BNI) were the first highly selective KOR antagonists to be discovered.[1]
See also
References
- ↑ 1.0 1.1 Portoghese PS, Lipkowski AW, Takemori AE (March 1987). "Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists". Life Sci. 40 (13): 1287–92. doi:10.1016/0024-3205(87)90585-6. PMID 2882399.